XNCR NASDAQ
Xencor, Inc.
1W: +20.2%
1M: +17.1%
3M: +53.6%
YTD: +101.0%
1Y: +127.0%
3Y: +64.9%
5Y: -21.3%
$29.99
+0.81 (+2.78%)
Weekly Expected Move ±8.0%
$21
$23
$25
$27
$29
Credit Risk of going bust: lower than 62% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.12 (down 99.6%), Xencor, Inc. would be worth roughly what it owes.
Total debt $65.2M against a stock market value of $2.23B.
Distance to default 6.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $32.6M (short-term plus half of long-term), stock volatility 63.6%; Altman Z'' 0.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.12 (down 99.6%), Xencor, Inc. would be worth roughly what it owes.
Total debt $65.2M against a stock market value of $2.23B.
Distance to default 6.51 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $32.6M (short-term plus half of long-term), stock volatility 63.6%; Altman Z'' 0.88. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.67
Bullish
3 bullish
1 neutral
0 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (87)
Xencor soars 16% on encouraging early XmAb819 data
At a glance: stocks gapping up premarket
Biggest stock movers Monday: XCNR, SGRY, AGEN
Xencor reports promising kidney cancer drug results, plans late-stage trial
What's next for personalized mRNA cancer vaccines?
William Blair refreshes its analyst conviction list
Xencor (NASDAQ:XNCR) Shares Up 4.6% – What’s Next?
Xencor, Inc. $XNCR Shares Newly Bought by Bank of America Corp DE
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Brokerages
Hsbc Holdings PLC Has $2.08 Million Position in Xencor, Inc. $XNCR
Jupiter Topco LLC Invests $386,000 in Xencor, Inc. $XNCR
Bank of New York Mellon Corp Makes New Investment in Xencor, Inc. $XNCR
William Blair updates its stock Conviction List
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of “Hold” by Brokerages
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
Biotech Breakout: What's in focus after Moderna's cancer win?
Xencor (NASDAQ:XNCR) Sets New 52-Week High – Should You Buy?
Dimensional Fund Advisors LP Buys 45,599 Shares of Xencor, Inc. $XNCR
Xencor (NASDAQ:XNCR) Reaches New 1-Year High Following Earnings Beat
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data - Seeking Alpha
Is Xencor (XNCR) Quietly Recasting Its Platform As A Solid-Tumor Oncology Story? - simplywall.st
Xencor (XNCR) Shares Jump 17% Following ESMO 2026 Announcement - GuruFocus
Sector Update: Healthcare Stocks Mixed Late Afternoon
$XNCR stock is up 11% today. Here's what we see in our data. - Quiver Quantitative
Xencor (NASDAQ:XNCR) Stock Price Up 7.9% - What's Next? - MarketBeat
Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Xencor: Bullish On Their Increasingly In-House Pipeline (NASDAQ:XNCR) - Seeking Alpha
Xencor (NASDAQ:XNCR) Shares Down 6.6% - Should You Sell? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xencor (XNCR) Rebounds Sharply, Is It Still A Bargain? - simplywall.st
(XNCR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
[Form 4] Xencor Inc Insider Trading Activity - Stock Titan
[Form 4] Xencor Inc Insider Trading Activity - Stock Titan
Xencor (XNCR) director granted RSUs and stock options in equity award - Stock Titan
Xencor (XNCR) director granted RSUs and 20,604 stock options at $12.20 - Stock Titan
Xencor (NASDAQ: XNCR) director receives new RSU and stock option grant - Stock Titan
Xencor (XNCR) awards RSUs and stock options to director Gorman - Stock Titan
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
XNCR Forecast — Price Target — Prediction for 2027 - TradingView
Xencor (XNCR) director’s 10b5-1 sale covers 6,843 common shares - Stock Titan
Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
These Analysts Think Xencor, Inc.'s (NASDAQ:XNCR) Sales Are Under Threat
Xencor GAAP EPS of -$1.71 misses by $0.96, revenue of $4.51M misses by $22.16M
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
Earnings Scheduled For May 6, 2026
Xencor Highlights XmAb942 Phase 1 Data, Previews TL1A/IL-23 Bispecific XmAb412 at DDW 2026
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Xencor (NASDAQ:XNCR) Stock Passes Above 50 Day Moving Average – Time to Sell?
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving Average – What’s Next?
Xencor (NASDAQ:XNCR) Shares Cross Above Fifty Day Moving Average – Here’s What Happened
This SAP Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of “Moderate Buy” from Analysts
Xencor, Inc. $XNCR Shares Purchased by DCF Advisers LLC
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling
Xencor falls as royalty dispute with Astra leads to guidance cut
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor GAAP EPS of -$0.09 beats by $0.50, revenue of $28.24M misses by $1.73M
Xencor: Q4 Earnings Snapshot
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
Xencor to Participate at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Analysts
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector
What Catalysts Are Rewriting The Xencor (XNCR) Story In A Recovering Biopharma Sector - Yahoo Finance
Xencor (NASDAQ:XNCR) Stock Passes Below Two Hundred Day Moving Average – What’s Next?
Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – What’s Next?
Could Early XmAb819 Signals Reshape Xencor’s (XNCR) Broader T‑Cell Engager Investment Narrative?
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Xencor (XNCR) Valuation Check After New Oncology And Autoimmune Pipeline Milestones
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings
Will Sharply Reduced Net Losses Signal a Turning Point for Xencor's (XNCR) Path to Profitability?